Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Mairinger, FD; Vollbrecht, C; Flom, E; Christoph, DC; Schmid, KW; Kollmeier, J; Popper, HH; Mairinger, T; Walter, RFH.
Folic acid phenotype (FAP) is a superior biomarker predicting response to pemetrexed-based chemotherapy in malignant pleural mesothelioma.
Oncotarget. 2017; 8(23):37502-37510
Doi: 10.18632/oncotarget.16398
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Popper Helmuth
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Malignant pleural mesothelioma (MPM) is a rare tumor linked to a dismal prognosis. Even the most effective chemotherapeutical regime of pemetrexed combined with cisplatin leads to a remission-rate of only about 40%. The reasons for the rather poor efficacy remain largely unknown. Phenotypes were significantly associated with progression (p=0.0279) and remission (p=0.0262). Cox-regression revealed significant associations between SLC19A1/TYMS-ratio (p=0.0076) as well as FPGS/TYMS-ratio (p=0.0026) and OS. For differentiation by risk-groups, COXPH identified a strong correlation (p=0.0008). 56 MPM specimens from patients treated with pemetrexed were used for qPCR analysis. Phenotypes and risk groups were defined by their expression levels of members of the folic acid metabolism and correlated to survival and objective response. Our results indicate that the balance between folic acid uptake, activation and metabolism plays a crucial role in response to pemetrexed-based chemotherapy and the prognosis of MPM patients. Implementing this marker profile in MPM stratification may help to individualize MPM-therapy more efficiently.
- Find related publications in this database (using NLM MeSH Indexing)
- Adult -
- Aged -
- Aged, 80 and over -
- Antineoplastic Combined Chemotherapy Protocols - therapeutic use
- Biomarkers, Tumor - metabolism
- Female -
- Folic Acid - metabolism
- Gene Expression Regulation, Neoplastic - drug effects
- Humans -
- Kaplan-Meier Estimate -
- Lung Neoplasms - drug therapy
- Lung Neoplasms - genetics
- Lung Neoplasms - metabolism
- Male -
- Mesothelioma - drug therapy
- Mesothelioma - genetics
- Mesothelioma - metabolism
- Middle Aged -
- Pemetrexed - administration & dosage
- Peptide Synthases - genetics
- Peptide Synthases - metabolism
- Phenotype -
- Pleural Neoplasms - drug therapy
- Pleural Neoplasms - genetics
- Pleural Neoplasms - metabolism
- Prognosis -
- Reduced Folate Carrier Protein - genetics
- Reduced Folate Carrier Protein - metabolism
- Thymidylate Synthase - genetics
- Thymidylate Synthase - metabolism
- Treatment Outcome -
- Find related publications in this database (Keywords)
- pleural mesothelioma
- pemetrexed
- thymidylate synthethase
- folylpolyglutamate synthase
- personalized therapy